Viewing nowCombinationJanuaTine Duo Sustained-release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Farmgen Science Co., Ltd.

MFDS item code 202300611 · Approved 2023.02.17 · Insurance code 670105440
Improvement of glycemic control in type 2 diabetes
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. Sitagliptin and metformin work together to efficiently help regulate blood sugar. This helps maintain blood sugar levels within a healthy range, supporting patients in achieving more stable blood glucose management. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was not completely dissolved and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). The 100/1000 mg extended-release tablet of this medicine is taken once daily as 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet of this medicine take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of the 50/1000 mg extended-release tablet of this medicine once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in a treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, provided that the following dose adjustments are made. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).
This medication contains two components, sitagliptin and metformin, and is used in diabetes treatment. Sitagliptin can rarely cause severe allergic reactions, so if symptoms such as skin rash, angioedema, or anaphylaxis occur, medication should be discontinued immediately. Additionally, acute pancreatitis, which is inflammation of the pancreas, can occur, so if symptoms such as abdominal pain, nausea, or vomiting appear, consult a healthcare professional promptly. Metformin can cause a rare complication called lactic acidosis, which is a serious condition resulting from excessive lactic acid accumulation in the body. Symptoms of lactic acidosis include muscle pain, weakness, difficulty breathing, and abdominal pain, so if any of these symptoms occur, the patient should stop the medication immediately and inform a healthcare professional. This medication should not be used in patients with moderate to severe renal impairment, acute heart failure, severe infections or dehydration, or in women who are pregnant or breastfeeding. Furthermore, the medication should be discontinued for a certain period before and after surgery and restarted only after renal function has returned to normal. During the use of this medication, there is a risk of hypoglycemia, especially when used in conjunction with insulin or sulfonylureas; hence, blood sugar levels should be monitored frequently, and attention should be paid to signs of hypoglycemia. Irregular meals, intense exercise, or combination with certain medications may also increase the risk of hypoglycemia or lactic acidosis, so caution is advised. If allergic to one of the ingredients, Red 40, caution should be exercised during administration. Long-term use requires regular blood tests to check kidney function and vitamin B12 levels; if vitamin B12 deficiency is suspected, appropriate supplementation is needed. Excessive alcohol consumption can increase the risk of lactic acidosis; thus, it is advisable to avoid drinking during medication use. During the use of this medication, if there is sudden difficulty in breathing, severe muscle pain, altered consciousness, skin rash, blisters, etc., consult a physician immediately. Finally, this medication is not recommended for children under 18 years of age as its safety and efficacy have not been established.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, rash, urticaria, cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is recommended to keep it at room temperature between 1°C and 30°C. Proper storage helps maintain the medication's effectiveness and prevent deterioration.
Light blue, biconvex, oval sustained-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Farmgen Science Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.